Loading...
Loading...
NASDAQ: MTSR
Healthcare · Biotechnology
Market Cap
$7.43B
52w High
$83.86
52w Low
$12.30
P/E
-23.55
Volume
27.87M
Outstanding Shares
105.38M
Skip DCF
The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.
Annual FCFF History
2
Derived observations
Positive FCFF Years
0
Total positive history
Positive Streak
0
Consecutive years
Latest FCFF
-$203.39M
Historical, not forecast
Is FCFF positive and has it been for 3+ consecutive years?
no
Latest FCFF is not positive.
Is there enough operating history to anchor a DCF?
no
Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.
Company profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
3
Buy
1
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 25, 2026
View
EPS
Actual vs estimate by quarter
-$1.03
-$0.85
-$0.66
-$0.66
-$1.11
-$0.56
—
Revenue
Actual vs estimate by quarter
—
—
—
—
—
—
—